DNTH vs KEY · rev $6.2M vs P/E 13, rev $7.51B
Dianthus Therapeutics Inc. (DNTH) versus KeyCorp (KEY) — a side-by-side from cached financials, not a winner call.
Dianthus Therapeutics Inc. (DNTH) is a biotechnology company listed on US.
KeyCorp (KEY) is a banks - regional company listed on US.
Latest reported DNTH revenue for 2024-12-31 was $6.2M. Net income was -$85.0M. Revenue was up 120.6% from 2023-12-31 to 2024-12-31. DNTH currently screens at market cap $4.40B.
Latest reported KEY revenue for 2025-12-31 was $7.51B. Net income was $1.83B. Revenue was up 62.7% from 2024-12-31 to 2025-12-31. KEY currently screens at market cap $22.64B and trailing P/E 12.8.
DNTH currently screens at market cap $4.40B. KEY currently screens at market cap $22.64B and trailing P/E 12.8.
Not investment advice. Open the DNTH and KEY stock pages for the full models.
Not investment advice.